Skip to content

US · OABIW · BIOTECHNOLOGY

OmniAb, Inc. (OABIW) intrinsic value and stock valuation

$0.09as of 2026-09-18 · Mkt cap 1.59B

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OmniAb, Inc. DCF and intrinsic value

InvestorsCraft values OABIW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OABIW’s statements →

OmniAb, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology EmeryVille, CA, US omniab.com

How the business is doing

Fiscal 2025–2019, USD

Revenue
$18.3T-7% 5y CAGRd
20252019
Net income
-$-13.59T
20252019
Free cash flow
-$-5.45T
20252019
Total equity
$218.2T-5.4% 5y CAGRd
20252019

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2019, USD
FYFYFYFYFY
Revenue$18.7T$26.4T$34.2T$59.1T$34.7T
Operating income-$-71.52T-$-74.5T-$-69.42T-$-26.65T-$-35.61T
Net income-$-64.78T-$-62.03T-$-50.62T-$-22.33T-$-27.04T
EPSd-$-570.06K-$-606K-$-507.8K-$-261.77K-$-235.51K
Operating cash flow-$-36.46T-$-39.66T$2.35T-$-3.59T-$-5.67T
Capital expenditure-$-565B-$-1.88T-$-1.64T-$-17.17T-$-4.07T
Free cash flow-$-37.02T-$-41.54T$703B-$-20.76T-$-9.74T
Total assets$300.9T$325.6T$375.2T$421.2T$304.5T
Total debt$20.3T$23.2T$25.6T$25.8T$13.9T
Net debt-$-5.19T-$-4.43T$9.2T-$-7.59T$13.9T
Total equity$267T$287.6T$314.6T$341.4T$234.3T
Cash and short-term investments$54T$59.4T$87T$88.3T$0.00
Income statement
FYFYFYFYFY
Revenue$18.7T$26.4T$34.2T$59.1T$34.7T
Cost of revenue$22.1T$0.00$0.00$0.00$0.00
Gross profit-$-3.39T$26.4T$34.2T$59.1T$34.7T
Research and development expenses$47.8T$55.1T$56.5T$48.4T$39.2T
Selling, general and administrative expenses$29.2T$30.7T$33.3T$24.9T$16.9T
Other expenses-$-8.84T$15T$13.7T$12.5T$14.2T
Operating expenses$68.1T$100.9T$103.6T$85.7T$70.4T
Cost and expenses$90.2T$100.9T$103.6T$85.7T$70.4T
Interest income$2.66T$3.11T$5.06T$587B$0.00
Interest expense$0.00$0.00$0.00$0.00$7B
Depreciation and amortization$21.8T$23.6T$19.5T$18.2T$16.3T
Ebitda-$-44.54T-$-47.83T-$-44.87T-$-7.81T-$-18.09T
Operating income-$-71.52T-$-74.5T-$-69.42T-$-26.65T-$-35.61T
Total other income/expenses, net$5.22T$3.09T$5.06T$587B$1.26T
Income before tax-$-66.29T-$-71.41T-$-64.36T-$-26.06T-$-34.35T
Income tax expense-$-1.52T-$-9.38T-$-13.74T-$-3.73T-$-7.31T
Net income-$-64.78T-$-62.03T-$-50.62T-$-22.33T-$-27.04T
Weighted average shares outstanding$113.6T$102.4T$99.7T$85.3T$114.8T
Weighted average diluted shares outstanding$113.6T$102.4T$99.7T$85.3T$114.8T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$54T$59.4T$87T$88.3T$0.00
Net receivables$7.39T$5.27T$3.84T$30.3T$21.1T
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$65.3T$68.1T$94.9T$125T$22.5T
Property, plant and equipment, net$25T$33.3T$38.1T$41.5T$20.1T
Goodwill and intangible assets$209.1T$222T$239.4T$251.2T$260.3T
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$235.6T$257.4T$280.3T$296.3T$281.9T
Total assets$300.9T$325.6T$375.2T$421.2T$304.5T
Accounts payable$1.88T$2.3T$4.41T$2.97T$2.92T
Short-term debt$3.88T$3.78T$3.49T$1.78T$578B
Deferred revenue$3.16T$2.34T$6.85T$8.21T$10.8T
Total current liabilities$16.3T$15.1T$23.1T$26T$20.6T
Long-term debt$16.5T$19.4T$22.1T$24T$13.3T
Deferred revenue, non-current$0.00$117B$862B$4.33T$9.23T
Total non-current liabilities$17.6T$22.9T$37.5T$53.8T$49.6T
Capital lease obligations$20.3T$23.2T$25.6T$25.8T$13.9T
Total liabilities$33.9T$37.9T$60.6T$79.8T$70.2T
Common stock$14B$12B$12B$12B$234.3T
Retained earnings-$-166.18T-$-101.4T-$-39.37T$11.3T$0.00
Accumulated other comprehensive income (loss)$12B$27B$50B$9B$0.00
Total equity$267T$287.6T$314.6T$341.4T$234.3T
Total investments$28.5T$31.8T$70.6T$54.9T$0.00
Total debt$20.3T$23.2T$25.6T$25.8T$13.9T
Net debt-$-5.19T-$-4.43T$9.2T-$-7.59T$13.9T
Cash flow statement
FYFYFYFYFY
Net income-$-64.78T-$-62.03T-$-50.62T-$-22.33T-$-27.04T
Depreciation and amortization$21.8T$23.6T$19.5T$18.2T$16.3T
Stock-based compensation$15.8T$21.5T$24.8T$18.3T$15.1T
Change in working capital-$-4.95T-$-10.17T$24.9T-$-10.83T-$-2.63T
Accounts receivable$189B-$-625B$26.9T-$-12.74T$6.02T
Inventory$0.00$0.00$0.00$0.00-$-1.51T
Accounts payable-$-231B-$-2.41T$920B$15.1T$1.51T
Net cash provided by operating activities-$-36.46T-$-39.66T$2.35T-$-3.59T-$-5.67T
Investments in property, plant and equipment-$-565B-$-1.88T-$-1.64T-$-17.17T-$-4.07T
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$6.47T$37.9T-$-18.38T-$-73.31T-$-4.03T
Common stock issued$28.4T$11.4T$0.00$96.2T$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.9T$13T-$-892B$110.7T$9.7T
Net change in cash-$-2.07T$11.2T-$-16.92T$33.4T$0.00
Cash at end of period$26.1T$28.2T$16.9T$33.4T$0.00
Operating cash flow-$-36.46T-$-39.66T$2.35T-$-3.59T-$-5.67T
Capital expenditure-$-565B-$-1.88T-$-1.64T-$-17.17T-$-4.07T
Free cash flow-$-37.02T-$-41.54T$703B-$-20.76T-$-9.74T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OmniAb, Inc.

        OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States. The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents. At the heart of the OmniAb platform are proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals have been genetically engineered to produce antibodies featuring human sequences, thereby streamlining the path to creating human therapeutic candidates. Beyond this core offering, OmniAb also addresses specific industry needs with specialized animal models: OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) facilitate bispecific antibody applications through a shared light chain mechanism. Additionally, OmniTaur provides a solution for challenging targets by leveraging the distinctive structural characteristics of cow antibodies.

        CEO
        Matthew W. Foehr
        Employees
        89
        Beta
        1.22

        Explore

        Frequently asked questions

        What is the intrinsic value of OmniAb, Inc. (OABIW)?

        InvestorsCraft does not currently publish an intrinsic value for OABIW. How the IC value is calculated.

        Is OABIW undervalued?

        InvestorsCraft does not publish an undervaluation signal for OABIW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.